Unknown
PHASE2
INTERVENTIONAL
NCT02252783
BFPET for Regional Myocardial Perfusion Imaging
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
BFPET will be evaluated as a diagnostic PET agent for assessing myocardial perfusion in subjects with known or suspected coronary artery disease (CAD) as compared to standard nuclear myocardial perfusion imaging (MPI). The safety of BFPET will be evaluated in known or suspected CAD subjects.
Interventions
Name:
BFPET
Type:
DRUG
Description:
Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
Primary Outcomes
Measure:
Sensitivity and specificity of BFPET
TimeFrame:
Up to 30 days
Description:
To evaluate the diagnostic performance of BFPET as a PET agent assessment of myocardial perfusion in known or suspected CAD subjects.
Trial Information
NCT ID
NCT02252783
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Fluoropharma, Inc.
Last Updated
December 15, 2025